Lattice Radiotherapy + Chemoimmunotherapy for Squamous Cell Carcinoma

This trial tests a combination of chemoimmunotherapy (a treatment combining chemotherapy and immunotherapy) and a specialized radiotherapy called lattice radiotherapy for treating squamous cell carcinoma, a type of throat cancer. The researchers aim to determine the optimal dose patients can tolerate while assessing the treatment's ability to shrink tumors. Individuals with a primary or lymph node tumor in the throat measuring at least 3 cm and a significant smoking history may qualify for this trial. As a Phase 1/Phase 2 trial, the research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group, offering participants the chance to contribute to groundbreaking cancer treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have demonstrated the safety of induction chemoimmunotherapy. One study found no treatment-related deaths and reported promising results in slowing disease progression. Most patients tolerated the treatment well, with few experiencing severe side effects.

Research on lattice radiotherapy (LRT) suggests it is a safe and effective option, particularly for large tumors. Studies have shown that LRT significantly reduces tumor size and is well-tolerated. Most patients experienced tumor shrinkage and symptom improvement, with few serious side effects.

Researchers are excited about these treatments because they combine Lattice Radiotherapy with Chemoimmunotherapy to tackle squamous cell carcinoma in an innovative way. Unlike traditional treatments like surgery, chemotherapy, or standard radiotherapy, Lattice Radiotherapy uses a unique pattern to deliver high doses of radiation to tumors while sparing surrounding healthy tissue. This precise targeting, combined with chemoimmunotherapy, aims to enhance the immune response against cancer cells. By potentially increasing effectiveness and reducing side effects, this approach offers a promising new option for patients with this type of cancer.

This trial will evaluate the combination of induction chemoimmunotherapy and lattice radiotherapy for treating squamous cell carcinoma. Research has shown that combining chemotherapy and immunotherapy, known as induction chemoimmunotherapy, yields promising results for this type of skin cancer. This combination improves survival rates, allowing patients to live longer without cancer spreading and reducing the chances of recurrence in the treated area. For lattice radiotherapy, a targeted radiation treatment, studies indicate it can shrink tumors by about 49% and achieve a six-month survival rate of about 79%. Patients often experience significant tumor shrinkage and symptom relief. This trial will explore how combining these treatments may enhance their overall effectiveness by leveraging both the body's immune response and precise radiation to manage large tumors.¹⁶⁷⁸⁹